Biosergen (BIOSGN) Q2 2026 earnings summary

Executive summary

• Significant strategic shift with a planned merger with Flerie to secure long-term funding and expertise for BSG005 clinical development.

• Development of BSG005 paused in April 2026 due to challenging financing environment; focus shifted to securing financial stability.

• Rights issue of SEK 40 million planned, fully covered by subscription and guarantee undertakings.

• BSG005 positioned as a first-line treatment for invasive fungal infections, with promising safety and efficacy data.

Financial highlights

• Net loss for Jan–Jun 2026 was SEK -10.5 million, improved from SEK -16.2 million year-over-year.

• EBITDA and operating loss both at SEK -10.5 million for the period.

• Cash and cash equivalents at period end were SEK 3.2 million, down from SEK 33.3 million a year earlier.

• Cash flow from operating activities was SEK -12.0 million, reflecting ongoing R&D and regulatory work.

• Equity at period end was SEK 0.7 million, down from SEK 32.6 million year-over-year.

Outlook and guidance

• Immediate priorities are executing the rights issue and completing the merger with Flerie.

• Continued focus on advancing BSG005 clinical development under new ownership structure.

• Market need for new antifungal therapies remains high due to rising incidence and resistance.